Clinical trials · Chicago, IL
Ulcerative Colitis clinical trials in Chicago
We’re tracking 30 recruiting ulcerative colitis studies with a site in or near Chicago — including Phase 1, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT07427017RecruitingPhase 2
Selenium for Ulcerative Colitis Patients on Biologics
This trial tests whether taking selenium supplements can help people with moderate to severe ulcerative colitis that is being treated with advanced therapies (biologics). The goal is to see if selenium can improve symptoms and reduce inflammation.
Chicago, IllinoisAges 18–85 - NCT02791854Enrolling by invitation
Improving Care for Adults With Crohn’s or Ulcerative Colitis
This trial looks at ways to improve care for adults living with inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. You may be invited if your clinic is part of an inflammatory bowel disease care network called IBD Qorus.
Chicago, IllinoisAges 18–99 - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Chicago, IllinoisAges 18 years+ - NCT05287126RecruitingPhase 2
Etrasimod for teens with active ulcerative colitis
This trial tests whether etrasimod can improve ulcerative colitis (UC) symptoms in adolescents with moderate to severe, active disease. It may help reduce inflammation and disease activity, especially if current treatments aren’t working well enough.
Chicago, IllinoisAges 12–17 - NCT06598943RecruitingPhase 2
Study of two new drugs for ulcerative colitis
This study tests two experimental drugs, Eltrekibart and Mirikizumab, for adults with moderate to severe ulcerative colitis who have not responded well to other treatments. The goal is to see if these drugs can help control the disease.
Chicago, IllinoisAges 18–75 - NCT07071519RecruitingPhase 3
Risankizumab for young people with ulcerative colitis
This study tests risankizumab (a medication that targets inflammation) in young people with ulcerative colitis who haven't improved enough on other treatments. It aims to see if risankizumab can help control symptoms and reduce bowel inflammation.
Chicago, IllinoisAges 2–17 - NCT06095128RecruitingPhase 4
Vedolizumab and tofacitinib study for ulcerative colitis
This trial tests if combining two medicines, vedolizumab and tofacitinib, helps control moderate to severe ulcerative colitis. It may be an option if other treatments, like anti-TNF drugs, haven't worked well for you.
Chicago, IllinoisAges 18–65 - NCT07483073RecruitingPhase 2
Study of new drugs for moderate to severe ulcerative colitis or Crohn's disease
This trial is testing multiple new drugs for people with moderate to severe ulcerative colitis or Crohn's disease who have not had success with at least one standard treatment. The goal is to find a better option that can help control symptoms and inflammation.
Chicago, IllinoisAges 18–80 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Chicago, IllinoisAges 18 years+ - NCT06693310Recruiting
Stopping therapy safely in ulcerative colitis with no inflammation
This trial tests whether people with ulcerative colitis who have been in deep remission (no signs of active disease) can safely reduce or stop their current medication. It aims to find out if careful monitoring can keep them healthy without full-dose treatment.
Chicago, IllinoisAges 18–75 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Chicago, IllinoisAges 18–75 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Chicago, IllinoisAges 16–80 - NCT06560021Enrolling by invitation
Random biopsies in inflammatory bowel disease surveillance
This trial looks at whether taking random biopsies during a routine colonoscopy is helpful for people with inflammatory bowel disease (IBD) who are at risk for colon cancer. It aims to understand if random biopsies can detect early signs of cancer or pre-cancer.
Chicago, IllinoisAges 18 years+ - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Chicago, IllinoisAges 18–70 - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Chicago, IllinoisAges 18–80 - NCT05230173Recruiting
Treat to endoscopic remission in inflammatory bowel disease
This study tests whether switching to a different treatment for inflammatory bowel disease (IBD) can achieve healing of the gut lining. It is for people whose symptoms are under control but who still have significant inflammation in their bowel.
Chicago, IllinoisAges 18 years+ - NCT06398626Recruiting
Observational study of etrasimod for ulcerative colitis
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
Chicago, IllinoisAges 18–64 - NCT07186101RecruitingPhase 2
Testing a new combo therapy for ulcerative colitis
This study tests two drugs together (LY4268989 and mirikizumab) in people with moderate to severe ulcerative colitis. It's for those whose current treatments didn't work well enough.
Chicago, IllinoisAges 18–80 - NCT06587828Recruiting
Looking at immune cells in people with autoimmune disease
This study collects blood, tissue, and other samples from people with autoimmune diseases like Crohn's disease, multiple sclerosis, or lupus. Researchers will study your immune cells (T cells) to learn what they are attacking, which could lead to better treatments in the future.
Skokie, IllinoisAges 18 years+ - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
Oak Lawn, IllinoisAges 18–80 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Park Ridge, IllinoisAges 2–17 - NCT06405087RecruitingPhase 3
Long-term study of vedolizumab for children with IBD
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
Park Ridge, IllinoisAges 2–17 - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Park Ridge, IllinoisAges 2–17 - NCT05442567RecruitingPhase 3
Vedolizumab study for kids with ulcerative colitis or Crohn’s
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
Park Ridge, IllinoisAges 2 years+
Hear when a new Ulcerative Colitis trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Ulcerative Colitis trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting ulcerative colitis studies listed above.
- University of Chicago · 8 studies
- Northwestern University · 7 studies
- Rush University Medical Center · 4 studies
- Advocate Children's Hospital - Park Ridge · 3 studies
- GI Alliance - Glenview · 3 studies
- GI Alliance · 2 studies
- Midwest Digestive Health & Nutrition · 2 studies
- Suburban Gastroenterology · 2 studies
What taking part in a ulcerative colitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting ulcerative colitis studies in Illinois.
Common questions
- Are there ulcerative colitis clinical trials near Chicago?
- Yes. We're currently tracking 30 recruiting ulcerative colitis studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ulcerative colitis study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ulcerative colitis studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.